Last reviewed · How we verify

Mepsevii — Competitive Intelligence Brief

Mepsevii (VESTRONIDASE ALFA) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lysosomal beta Glucuronidase [EPC]. Area: Metabolic.

marketed Lysosomal beta Glucuronidase [EPC] Metabolic Enzyme Live · refreshed every 30 min

Target snapshot

Mepsevii (VESTRONIDASE ALFA) — Ultragenyx Pharm Inc. Mepsevii works by replacing the deficient enzyme beta-glucuronidase in patients with MPS-VII.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Mepsevii TARGET VESTRONIDASE ALFA Ultragenyx Pharm Inc marketed Lysosomal beta Glucuronidase [EPC] 2017-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lysosomal beta Glucuronidase [EPC] class)

  1. Ultragenyx Pharm Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mepsevii — Competitive Intelligence Brief. https://druglandscape.com/ci/vestronidase-alfa. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: